Medeon Biodesign (6499) — Financial Flexibility Index
Medeon Biodesign (6499) has a Financial Flexibility Index of -0.46x as of June 2025. Free cash flow of NT$-131.51 Million (operating CF NT$-133.97 Million minus capex NT$2.46 Million) represents 0% of total liabilities (NT$284.53 Million). Check 6499 PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Medeon Biodesign Financial Flexibility Index (2017–2024)
Historical Financial Flexibility Index trend for Medeon Biodesign across 8 annual periods. See Medeon Biodesign short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Annual Financial Flexibility Index for Medeon Biodesign (2017–2024)
Year-by-year free cash flow to debt coverage for Medeon Biodesign. For the full company profile including market capitalisation, see market value of Medeon Biodesign.
| Year | Flexibility Index | Free Cash Flow (TWD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2024 | -2.22x | NT$-757.89 Million | NT$-832.66 Million | NT$341.84 Million | ▼ -19.1% |
| 2023 | -1.86x | NT$-699.26 Million | NT$-755.08 Million | NT$375.65 Million | ▼ -118.5% |
| 2022 | -0.85x | NT$-320.77 Million | NT$-461.34 Million | NT$376.48 Million | ▲ +47.4% |
| 2021 | -1.62x | NT$-285.06 Million | NT$-293.38 Million | NT$176.00 Million | ▼ -723.7% |
| 2020 | -0.20x | NT$-131.11 Million | NT$-151.27 Million | NT$666.83 Million | ▲ +72.7% |
| 2019 | -0.72x | NT$-193.09 Million | NT$-241.99 Million | NT$268.18 Million | ▼ -128.7% |
| 2018 | 2.51x | NT$373.19 Million | NT$322.05 Million | NT$148.89 Million | ▲ +262.9% |
| 2017 | -1.54x | NT$-162.21 Million | NT$-310.76 Million | NT$105.41 Million | — |